Sugi Predict

Sugi Predict / Compounds / SCHEMBL1521817

SCHEMBL1521817

SCHEMBL1521817

CCN1C(=O)N(c2ccc(F)c(NC(=O)Nc3cc(C(F)(F)F)ccc3F)c2)Cc2cnc(NC)cc21

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BRAF P15056 7/20 0.40
▸ KDR P35968 9/20 0.39
▸ FGFR1 P11362 2/20 0.38
▸ FGFR4 P22455 2/20 0.38
▸ PDGFRB P09619 3/20 0.38
▸ RAF1 P04049 2/20 0.37
▸ KRAS P01116 1/20 0.37
▸ MAP2K2 P36507 1/20 0.37
▸ MAP2K1 Q02750 1/20 0.37
▸ KIT P10721 2/20 0.37
▸ PDGFRA P16234 1/20 0.37
▸ TEK Q02763 1/20 0.37
▸ FLT3 P36888 2/20 0.37
▸ MEN1 O00255 1/20 0.37
▸ TSHR P16473 1/20 0.37
▸ KMT2A Q03164 1/20 0.37
▸ NTRK1 P04629 1/20 0.37
▸ RET P07949 1/20 0.37
▸ LTK P29376 1/20 0.37
▸ CDK8 P49336 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1521993 0.91 KDR (0.39) BRAFKDRFGFR1FGFR4PDGFRB
SCHEMBL1521600 0.85 KRAS (0.37) BRAFKDRFGFR1FGFR4RAF1
SCHEMBL1521812 0.85 KIT (0.40) BRAFKDRFGFR1FGFR4RAF1
SCHEMBL1522039 0.85 FGFR4 (0.44) BRAFKDRFGFR1FGFR4PDGFRB
SCHEMBL1521747 0.85 KIT (0.38) BRAFKDRFGFR1FGFR4RAF1
SCHEMBL1521807 0.85 MAPK14 (0.43) BRAFKDRRAF1KRASMAP2K2
SCHEMBL1521987 0.84 FGFR1 (0.43) FGFR1FGFR4KITPDGFRAKMT2A
SCHEMBL1521613 0.84 BRAF (0.42) BRAFKDRFGFR1FGFR4RAF1
SCHEMBL1522009 0.84 BRAF (0.56) BRAFKDRFGFR1FGFR4RAF1
SCHEMBL1521624 0.83 BRAF (0.44) BRAFKDRFGFR1FGFR4RAF1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110118271-A1 Kinase Inhibitors Useful For The Treatment Of Proliferative Diseases FLYNN DANIEL L 2011-05-19 — — US claimed
US-20090099190-A1 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PHARMACEUTICALS, LLC (US) 2009-04-16 — — US claimed
US-20110118271-A1 Kinase Inhibitors Useful For The Treatment Of Proliferative Diseases FLYNN DANIEL L 2011-05-19 — — US disclosed
US-7897762-B2 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PHARMACEUTICALS, LLC (US) 2011-03-01 — — US disclosed
US-20090099190-A1 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PHARMACEUTICALS, LLC (US) 2009-04-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110118271-A1 Kinase Inhibitors Useful For The Treatment Of Proliferative Diseases BRAF, PRKDC, RAF1 BRAF 1/4885KDR 500/4885FGFR1 577/4885
US-20090099190-A1 Kinase inhibitors useful for the treatment of proliferative diseases BRAF, PRKDC, RAF1 BRAF 1/4885KDR 500/4885FGFR1 577/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.